Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria

Marcus Maurer,Martin Metz,John Anderson, Neetu Talreja, Hugh Windom,Diego Alvarado,Elizabeth Crowley,Diane Young,Kunal Merchant, ELsa Paradise,Margo Heath-Chiozzi,Jonathan Bernstein

Journal of Allergy and Clinical Immunology（2023）

引用 1|浏览20

暂无评分

摘要

Mast cells (MCs) are key effector cells in chronic spontaneous urticaria (CSU). Barzolvolimab (BAR/CDX-0159), a monoclonal anti-KIT antibody, has been demonstrated to deplete skin MCs in chronic inducible urticaria and reduce disease activity. Here, we report BAR safety and efficacy in antihistamine-refractory CSU patients.

查看译文

关键词

chronic spontaneous urticaria,barzolvolimab,antibody,multiple doses,anti-kit

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要